全文获取类型
收费全文 | 9532篇 |
免费 | 497篇 |
国内免费 | 74篇 |
专业分类
耳鼻咽喉 | 75篇 |
儿科学 | 162篇 |
妇产科学 | 198篇 |
基础医学 | 1058篇 |
口腔科学 | 189篇 |
临床医学 | 759篇 |
内科学 | 2686篇 |
皮肤病学 | 156篇 |
神经病学 | 999篇 |
特种医学 | 426篇 |
外科学 | 1328篇 |
综合类 | 27篇 |
预防医学 | 387篇 |
眼科学 | 76篇 |
药学 | 587篇 |
中国医学 | 13篇 |
肿瘤学 | 977篇 |
出版年
2024年 | 10篇 |
2023年 | 68篇 |
2022年 | 138篇 |
2021年 | 259篇 |
2020年 | 184篇 |
2019年 | 180篇 |
2018年 | 249篇 |
2017年 | 192篇 |
2016年 | 240篇 |
2015年 | 271篇 |
2014年 | 391篇 |
2013年 | 458篇 |
2012年 | 763篇 |
2011年 | 735篇 |
2010年 | 414篇 |
2009年 | 421篇 |
2008年 | 666篇 |
2007年 | 677篇 |
2006年 | 613篇 |
2005年 | 633篇 |
2004年 | 525篇 |
2003年 | 479篇 |
2002年 | 460篇 |
2001年 | 81篇 |
2000年 | 70篇 |
1999年 | 67篇 |
1998年 | 92篇 |
1997年 | 72篇 |
1996年 | 61篇 |
1995年 | 60篇 |
1994年 | 42篇 |
1993年 | 50篇 |
1992年 | 56篇 |
1991年 | 32篇 |
1990年 | 40篇 |
1989年 | 50篇 |
1988年 | 38篇 |
1987年 | 31篇 |
1986年 | 25篇 |
1985年 | 23篇 |
1984年 | 14篇 |
1983年 | 17篇 |
1982年 | 16篇 |
1981年 | 16篇 |
1980年 | 26篇 |
1978年 | 7篇 |
1977年 | 8篇 |
1976年 | 7篇 |
1974年 | 12篇 |
1971年 | 6篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Borrelli Enrico Grosso Domenico Vella Giovanna Sacconi Riccardo Battista Marco Querques Lea Zucchiatti Ilaria Prascina Francesco Bandello Francesco Querques Giuseppe 《Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie》2020,258(12):2621-2628
Graefe's Archive for Clinical and Experimental Ophthalmology - To estimate the impact of delayed care during the coronavirus disease 2019 (COVID-19) pandemic on the outcomes of patients with... 相似文献
2.
Alessandro Vatrella Angelantonio Maglio Corrado Pelaia Girolamo Pelaia Carolina Vitale 《Expert opinion on pharmacotherapy》2020,21(12):1505-1515
ABSTRACT
Introduction
‘Critical Asthma Syndrome’ (CAS) is an umbrella term proposed to include several forms of asthma, responsible for acute and life-threatening exacerbations. CAS requires urgent and adequate supportive and pharmacological treatments to prevent serious outcomes. 相似文献3.
4.
5.
Julie A. Schmidt Georgina K. Fensom Sabina Rinaldi Augustin Scalbert Paul N. Appleby David Achaintre Audrey Gicquiau Marc J. Gunter Pietro Ferrari Rudolf Kaaks Tilman Kühn Heiner Boeing Antonia Trichopoulou Anna Karakatsani Eleni Peppa Domenico Palli Sabina Sieri Rosario Tumino Bas Bueno-de-Mesquita Antonio Agudo Maria-Jose Sánchez María-Dolores Chirlaque Eva Ardanaz Nerea Larrañaga Aurora Perez-Cornago Nada Assi Elio Riboli Konstantinos K. Tsilidis Timothy J. Key Ruth C. Travis 《International journal of cancer. Journal international du cancer》2020,146(3):720-730
Metabolomics may reveal novel insights into the etiology of prostate cancer, for which few risk factors are established. We investigated the association between patterns in baseline plasma metabolite profile and subsequent prostate cancer risk, using data from 3,057 matched case–control sets from the European Prospective Investigation into Cancer and Nutrition (EPIC). We measured 119 metabolite concentrations in plasma samples, collected on average 9.4 years before diagnosis, by mass spectrometry (AbsoluteIDQ p180 Kit, Biocrates Life Sciences AG). Metabolite patterns were identified using treelet transform, a statistical method for identification of groups of correlated metabolites. Associations of metabolite patterns with prostate cancer risk (OR1SD) were estimated by conditional logistic regression. Supplementary analyses were conducted for metabolite patterns derived using principal component analysis and for individual metabolites. Men with metabolite profiles characterized by higher concentrations of either phosphatidylcholines or hydroxysphingomyelins (OR1SD = 0.77, 95% confidence interval 0.66–0.89), acylcarnitines C18:1 and C18:2, glutamate, ornithine and taurine (OR1SD = 0.72, 0.57–0.90), or lysophosphatidylcholines (OR1SD = 0.81, 0.69–0.95) had lower risk of advanced stage prostate cancer at diagnosis, with no evidence of heterogeneity by follow-up time. Similar associations were observed for the two former patterns with aggressive disease risk (the more aggressive subset of advanced stage), while the latter pattern was inversely related to risk of prostate cancer death (OR1SD = 0.77, 0.61–0.96). No associations were observed for prostate cancer overall or less aggressive tumor subtypes. In conclusion, metabolite patterns may be related to lower risk of more aggressive prostate tumors and prostate cancer death, and might be relevant to etiology of advanced stage prostate cancer. 相似文献
6.
D. Sforza G. Iaria L. Petagna A. Parente A. Anselmo F. Sergi S. Marzio F. Corrado S. Telli T.M. Manzia G. Tisone 《Transplantation proceedings》2019,51(1):140-142
Background
One daily dose of tacrolimus (QDT) improves adherence in kidney transplant (KT) recipients. A switch from twice-daily tacrolimus (BDT) to QDT showed similar efficacy and safety.Methods
The aim of our study was to demonstrate the long-term efficacy and safety of switching from BDT to QDT in KT recipients. Preliminary results have already been published. Forty-one patients (34 men and 7 women), mean age at KT of 43.9 ± 12.7 years, underwent a 1:1 dose switch from BDT to QDT; the mean time from KT to switch was 36.6 ± 16.1 months. In our study population, 4 patients received a living donor KT and 2 received a second allograft.Results
The mean follow-up was 86.8 ± 13 months from the switch and 126.2 ± 22.3 months from KT. Graft and patient survival rates were 90.2% and 95.1%, respectively. All patients maintained stable renal function during follow-up. During the first 3 months after the switch we observed a significant decrease in tacrolimus blood level (P = .0001). No significant differences were observed regarding tacrolimus dose before and after QDT introduction (P = not significant [NS]). Fourteen patients who stopped steroids under BDT treatment and 16 patients who stopped steroids after the switch are currently steroid-free.Conclusion
Our study showed safety and efficacy in switching from BDT to QDT. After early (<1 year) dose adjustment, tacrolimus blood levels remained stable throughout follow-up. Moreover, QDT represented a valid alternative for patients showing steroid side effects. 相似文献7.
8.
9.
10.
Nicola Martinelli Domenico Girelli Paolo Ferraresi Oliviero Olivieri Barbara Lunghi Franco Manzato Roberto Corrocher Francesco Bernardi 《Blood coagulation & fibrinolysis》2007,18(2):125-129
A common factor V gene haplotype, the FVR2 haplotype (FVHR2), has been associated with a reduced cofactor activity in activated protein C-mediated activated factor VIII inactivation. Our aim was to investigate the role of FVHR2 as a possible determinant of factor VIII levels in a population study. A total of 516 individuals (401 men, 115 women; mean age 58.4 +/- 10.8 years) were enrolled within the frame of a regional cardiovascular survey, characterized for factor VIII coagulant activity (FVIII:c) and factor V coagulant activity (FV:c) levels, and genotyped for factor V polymorphisms. In men without signs of overt inflammation, FVHR2 carriers had higher levels of FVIII:c than noncarriers (154 IU/dl, 95% confidence interval = 143-166 versus 142 IU/dl, 95% confidence interval = 138-147; P = 0.045) and were more represented in individuals with high (> or = 150 IU/dl) FVIII:c levels (21.2 versus 10.8%; odds ratio = 2.27, 95% confidence interval = 1.17-4.39 after adjustment for age, blood group and high-sensitivity C-reactive protein levels). In conclusion, this clinical report suggests the common FVHR2 as a possible independent determinant of FVIII:c levels. The report concomitantly addresses the relationship between factor V and factor VIII levels and supports the hypothesis of a mild prothrombotic role of FVHR2 by means of increased factor VIII levels. 相似文献